Literature DB >> 1388847

New carriers and adjuvants in the development of vaccines.

G Del Giudice1.   

Abstract

Different approaches are being followed to enhance the immunogenicity of established and newly developed vaccines. Some of them foresee the utilization of carrier molecules recognized by the immune systems of a large proportion of the human population. Others are directed mainly towards the development of improved adjuvants and delivery systems.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1388847     DOI： 10.1016/s0952-7915(06)80038-5

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN： 0952-7915            Impact factor:   7.486


  10 in total

1.  N19 polyepitope as a carrier for enhanced immunogenicity and protective efficacy of meningococcal conjugate vaccines.

Authors:  Karin Baraldo; Elena Mori; Antonella Bartoloni; Roberto Petracca; Aldo Giannozzi; Francesco Norelli; Rino Rappuoli; Guido Grandi; Giuseppe Del Giudice
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

2.  Synthetic peptides non-covalently bound to bacterial hsp 70 elicit peptide-specific T-cell responses in vivo.

Authors:  E Román; C Moreno
Journal:  Immunology       Date:  1996-08       Impact factor: 7.397

3.  The MultiTEP platform-based Alzheimer's disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates.

Authors:  Hayk Davtyan; Anahit Ghochikyan; Irina Petrushina; Armine Hovakimyan; Arpine Davtyan; David H Cribbs; Michael G Agadjanyan
Journal:  Alzheimers Dement       Date:  2014-02-20       Impact factor: 21.566

4.  Calix[n]arene-based immunogens: A new non-proteic strategy for anti-cocaine vaccine.

Authors:  Leonardo da Silva Neto; Angélica Faleiros da Silva Maia; Adriana Martins Godin; Paulo Sérgio de Almeida Augusto; Raissa Lima Gonçalves Pereira; Sordaini Maria Caligiorne; Rosemeire Brondi Alves; Simone Odília Antunes Fernandes; Valbert Nascimento Cardoso; Gisele Assis Castro Goulart; Felipe Terra Martins; Maila de Castro Lourenço das Neves; Frederico Duarte Garcia; Ângelo de Fátima
Journal:  J Adv Res       Date:  2021-09-13       Impact factor: 12.822

5.  Successful primate immunization with peptides conjugated to purified protein derivative or mycobacterial heat shock proteins in the absence of adjuvants.

Authors:  R Perraut; A R Lussow; S Gavoille; O Garraud; H Matile; C Tougne; J van Embden; R van der Zee; P H Lambert; J Gysin
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

6.  Synthetic peptides representing T-cell epitopes act as carriers in pneumococcal polysaccharide conjugate vaccines.

Authors:  E A de Velasco; D Merkus; S Anderton; A F Verheul; E F Lizzio; R Van der Zee; W Van Eden; T Hoffman; J Verhoef; H Snippe
Journal:  Infect Immun       Date:  1995-03       Impact factor: 3.441

7.  Heat shock proteins as carrier molecules: in vivo helper effect mediated by Escherichia coli GroEL and DnaK proteins requires cross-linking with antigen.

Authors:  C Barrios; C Georgopoulos; P H Lambert; G Del Giudice
Journal:  Clin Exp Immunol       Date:  1994-11       Impact factor: 4.330

8.  Specificity of antibodies induced after immunization of mice with the mycobacterial heat shock protein of 65 kD.

Authors:  C Barrios; C Tougne; B S Polla; P H Lambert; G Del Giudice
Journal:  Clin Exp Immunol       Date:  1994-11       Impact factor: 4.330

Review 9.  Hsp70: a carrier molecule with built-in adjuvanticity.

Authors:  G Del Giudice
Journal:  Experientia       Date:  1994-11-30

Review 10.  Factors contributing to the immunogenicity of meningococcal conjugate vaccines.

Authors:  Michael Bröker; Francesco Berti; Paolo Costantino
Journal:  Hum Vaccin Immunother       Date:  2016-03-02       Impact factor: 3.452
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.